Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM012
- Development stage
- Phase 3
- Lead developer
- Mediforum
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PM012 is a botanical drug candidate developed by Mediforum for the treatment of mild to moderate Alzheimer's disease. It is a standardized oral formulation consisting of extracts from seven traditional medicinal herbs: *Rehmannia glutinosa*, *Lycium chinense*, *Dioscorea batatas*, *Cornus officinalis*, *Poria cocos*, *Paeonia suffruticosa*, and *Panax ginseng*. The therapeutic rationale for PM012 is based on its multi-target approach, which includes the inhibition of amyloid-beta (Aβ) aggregation, reduction of neuroinflammation, and enhancement of cholinergic activity. In clinical studies, PM012 has been compared to donepezil to evaluate its efficacy in improving cognitive scores (such as ADAS-cog) and its safety profile. It is currently in Phase 2b development in South Korea, with plans for Phase 3 trials, positioning it as a potential natural-product-based alternative to existing acetylcholinesterase inhibitors.
- Other names
- Myung-Moon 012Myung-Moon012Myung-Moon-012
02
Targets
BDNF (Brain-derived neurotrophic factor)CaV (Voltage-gated calcium channel protein complex)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on PM012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM012.